» Articles » PMID: 37981023

Persistent Use of Dupilumab in Adults with Asthma or Chronic Rhinosinusitis with Nasal Polyps

Overview
Authors
Affiliations
Soon will be listed here.
Citing Articles

Trends in dupilumab persistence among patients with chronic rhinosinusitis with nasal polyps.

Stack T, Zaidi S, Dickerson T, Pate V, Monk A, Benaim E Rhinol Online. 2024; 7(8):69-74.

PMID: 39247706 PMC: 11378963. DOI: 10.4193/rhinol/24.003.

References
1.
Silverberg J, Guttman-Yassky E, Gadkari A, Kuznik A, Mallya U, Mastey V . Real-world persistence with dupilumab among adults with atopic dermatitis. Ann Allergy Asthma Immunol. 2020; 126(1):40-45. DOI: 10.1016/j.anai.2020.07.026. View

2.
Canonica G, Bourdin A, Peters A, Desrosiers M, Bachert C, Weidinger S . Dupilumab Demonstrates Rapid Onset of Response Across Three Type 2 Inflammatory Diseases. J Allergy Clin Immunol Pract. 2022; 10(6):1515-1526. DOI: 10.1016/j.jaip.2022.02.026. View

3.
Laidlaw T, Mullol J, Fan C, Zhang D, Amin N, Khan A . Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD. J Allergy Clin Immunol Pract. 2019; 7(7):2462-2465.e1. DOI: 10.1016/j.jaip.2019.03.044. View

4.
Castro M, Corren J, Pavord I, Maspero J, Wenzel S, Rabe K . Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med. 2018; 378(26):2486-2496. DOI: 10.1056/NEJMoa1804092. View

5.
Harb H, Chatila T . Mechanisms of Dupilumab. Clin Exp Allergy. 2019; 50(1):5-14. PMC: 6930967. DOI: 10.1111/cea.13491. View